Melanoma and Brain Metastases
4 clinical trials · Condition
◉ Watch Melanoma and Brain Metastases
| Record | Firm | Date |
|---|---|---|
| Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases (NCT06887088) | Grupo Español Multidisciplinar de Melanoma | 2025-05-29 |
| Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites (NCT01978236) | GlaxoSmithKline | 2014-04-08 |
| Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain (NCT02039947) | Novartis Pharmaceuticals | 2014-02-21 |
| A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain (NCT01266967) | GlaxoSmithKline | 2011-02-01 |
Track Melanoma and Brain Metastases automatically
Every clearance here is in the API, with alerts when new ones post.